Abstract: The present invention relates to the technical field of photosensitizers, and particularly to a near-infrared nano-photosensitizer and a preparation method and use thereof. The near-infrared nano-photosensitizer in the present invention is modified by conjugation extension of the boron dipyrromethene core, achieving absorption and emission spectra close to the near-infrared region. A polyfluoroalkyl group and a polyethylene glycol group are introduced to the boron dipyrromethene structure to obtain an amphiphilic photosensitizer. By means of the strong fluorine-fluorine interaction between the polyfluoroalkyl group and the hydrophilic interaction of the polyethylene glycol group, a nano-photosensitive micelle with an ultra-low CMC value is ultimately constructed. Boron dipyrromethene is induced by fluorine-fluorine interaction to undergo J-aggregation, causing the maximum absorption peak to red-shift to the near-infrared region, beneficial to the deep phototherapy of tumors.
Type:
Grant
Filed:
January 25, 2022
Date of Patent:
April 16, 2024
Assignee:
SOOCHOW UNIVERSITY
Inventors:
Zhengqing Guo, Hui He, Mengke Shi, Han Xu, Dandan Ji, Yangyang Huang, Qiujin He
Abstract: Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.
Type:
Grant
Filed:
July 13, 2021
Date of Patent:
February 6, 2024
Assignee:
Northwestern University
Inventors:
Thomas A. Mustoe, Robert D. Galiano, Seok Jong Hong, Ping Xie, Shengxian Jia
Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an organic acid excipient, and a basic drug are described, along with related methods.
Type:
Grant
Filed:
March 22, 2021
Date of Patent:
December 19, 2023
Assignee:
Heron Therapeutics, Inc.
Inventors:
Thomas B. Ottoboni, Lee Ann Lynn Girotti
Abstract: The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor.
Abstract: The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases.
Type:
Grant
Filed:
November 21, 2017
Date of Patent:
October 24, 2023
Assignee:
The General Hospital Corporation
Inventors:
Tayyaba Hasan, Ulysses W. Sallum, Sarika Verma, Gerard Nau
Abstract: The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, particularly involved in hypersensitive cough or itching.
Abstract: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
August 8, 2023
Assignee:
University of Florida Research Foundation, Incorporated
Abstract: Disclosed herein are compositions for treating cancer comprising a modified veratridine. In certain aspects, the modified veratridine comprises a polyglutamic acid (PLE) or polyethylene glycol/polyglutamic acid (PEG-PLE) conjugated to the 4? hemiketal thereof. Further disclosed is a method of treating colorectal cancer in a subject comprising administering to a subject an effective amount of the disclosed compositions.
Abstract: The present invention provides methods and compositions for treating cancer by administering an EP4 antagonist in combination with radiation therapy, antibody therapy and/or anti-metabolite chemotherapy.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
July 25, 2023
Assignee:
EISAI R&D MANAGEMENT CO., LTD.
Inventors:
Xingfeng Bao, Diana Albu, Mary Woodall-Jappe
Abstract: Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
Abstract: A leather-like hybrid mycelial cellulose sheet and production thereof. Precise selection of mushroom species and reagents allows for production at low pH, thereby resulting in a strong, flexible, and dry leather-like material suitable for application in various industries.
Type:
Grant
Filed:
May 24, 2022
Date of Patent:
April 11, 2023
Assignee:
VU MON TECHNICAL AND TECHNOLOGY CO., LTD.
Abstract: Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
Abstract: Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.
Abstract: This invention relates to the use of at least one following compound having formula (I), as well as the salts thereof, the optical and geometric isomers thereof, and the solvates thereof, as deodorant agent for treating body odor, preferably underarm odor:
Abstract: The disclosure relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., diabetes mellitus, chronic kidney disease, acute kidney failure, and reduction of blood glucose levels.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
November 8, 2022
Assignee:
INTRA-CELLULAR THERAPIES, INC.
Inventors:
Peng Li, Youyi Peng, Lawrence P. Wennogle, Qiang Zhang
Abstract: There is provided a compound of formula I or a pharmacologically acceptable salt thereof: for use in the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumor, a metastatic brain cancer and primary CNS lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula I or a pharmacologically acceptable salt thereof.
Abstract: The present invention relates to the detection or diagnosis of infection or inflammation in a patient. In particular, the invention provides methods that allow the detection of markers in a sample from a patient or subject, such as a blood sample, which will indicate whether the patient or subject has an infection or has an inflammatory response.
Abstract: An aqueous ibuprofen and paracetamol composition has a pH 6.3-7.3. The composition can be used as a medicament, especially for the treatment of pain and/or inflammation. The composition can be formulated for intravenous injection.